Fiche publication
Date publication
juillet 2026
Journal
RSC advances
Auteurs
Membres identifiés du Cancéropôle Est :
Pr SCHNEIDER Raphaël
,
Pr ALEM-MARCHAND Halima
Tous les auteurs :
Gackowski M, Mlynarczyk DT, Alem H, Budna-Tukan J, Osmałek T, Schneider R
Lien Pubmed
Résumé
Titanium dioxide (TiO) is a widely used UV-shielding excipient for topical pharmaceutical and cosmetic formulations, but its ability to generate reactive oxygen species under UV irradiation limits its safety. Here, we report a MOF-derived TiO/CeO heterostructure designed to suppress TiO photoactivity while preserving its UV-protective properties. Under UVA irradiation, CeO incorporation strongly inhibits superoxide radical generation and reduces hydroxyl radical formation by 58% compared with rutile TiO. Importantly, this reduced photoactivity translates into improved pharmaceutical performance: in hydrogel formulations, 0.1 wt% TiO/CeO protects ketoprofen more effectively than TiO (77.54% 52.56% remaining after irradiation), while 0.5 wt% TiO/CeO provides almost complete photoprotection. The composite also has a lower impact on hydrogel matrix stability than pristine TiO and shows no acute toxicity in the Microtox assay. Overall, these results demonstrate that TiO/CeO heterostructuring is an effective, safe-by-design strategy for developing photoprotective excipients that stabilize photosensitive drugs in topical formulations.
Référence
RSC Adv. 2026 07 28;:
